Table 3.
Multivariable analyses for acute GVHD grade 2 to 4 and Rel/prog and association with combined biological models
| HLA-DPB1 matching | Categories | aGVHD grade 2 to 4 (N = 860, events = 297)* | Rel/prog (N = 837, events = 302)*† | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Events/n | HR | 95% CI | P | Events/n | HR | 95% CI | P | ||||
| TCE3.1 and PIRCHE II | Matched | 67/250 | 1.00 | — | 96/237 | 1.00 | — | ||||
| Nonpermissive, no PIRCHE II | 13/51 | 0.85 | 0.47 | 1.53 | .58 | 20/49 | 0.87 | 0.53 | 1.42 | .57 | |
| Nonpermissive, PIRCHE II | 102/237 | 1.73 | 1.27 | 2.37 | <.001 | 71/235 | 0.65 | 0.47 | 0.88 | .005 | |
| Permissive, no PIRCHE II | 31/91 | 1.28 | 0.84 | 1.97 | .25 | 36/95 | 0.88 | 0.59 | 1.29 | .50 | |
| Permissive, PIRCHE II | 84/231 | 1.40 | 1.01 | 1.93 | .04 | 79/221 | 0.77 | 0.57 | 1.03 | .08 | |
| TCE4.1 and PIRCHE II | Matched | 67/250 | 1.00 | — | 96/237 | 1.00 | — | ||||
| Nonpermissive, no PIRCHE II | 25/91 | 0.93 | 0.59 | 1.48 | .77 | 33/92 | 0.75 | 0.50 | 1.12 | .15 | |
| Nonpermissive, PIRCHE II | 131/312 | 1.67 | 1.24 | 2.25 | .001 | 94/311 | 0.64 | 0.48 | 0.85 | .002 | |
| Permissive, no PIRCHE II | 19/51 | 1.48 | 0.89 | 2.48 | .13 | 23/52 | 1.15 | 0.72 | 1.82 | .56 | |
| Permissive, PIRCHE II | 55/156 | 1.35 | 0.94 | 1.93 | .10 | 56/145 | 0.85 | 0.61 | 1.19 | .34 | |
| Expression and PIRCHE II | Matched | 67/250 | 1.00 | — | 96/237 | 1.00 | — | ||||
| R-high, no PIRCHE II‡ | 9/13 | NI | NI | NI | NI | 4/11 | NI | NI | NI | NI | |
| R-high, PIRCHE II | 62/155 | 1.72 | 1.21 | 2.44 | .002 | 40/149 | 0.61 | 0.42 | 0.88 | .008 | |
| R-low, no PIRCHE II | 10/42 | 0.86 | 0.44 | 1.67 | .66 | 16/42 | 0.72 | 0.42 | 1.23 | .23 | |
| R-low, PIRCHE II | 43/121 | 1.30 | 0.88 | 1.92 | .19 | 56/119 | 0.95 | 0.68 | 1.32 | .75 | |
| Expression and TCE3.1 | Matched | 67/250 | 1.00 | — | 96/237 | 1.00 | — | ||||
| R-high, nonpermissive | 39/89 | 1.87 | 1.26 | 2.80 | .002 | 26/86 | 0.73 | 0.47 | 1.13 | .15 | |
| R-high, permissive | 32/79 | 1.79 | 1.17 | 2.73 | .008 | 18/74 | 0.55 | 0.33 | 0.92 | .02 | |
| R-low, nonpermissive | 11/36 | 1.10 | 0.58 | 2.10 | .77 | 19/35 | 1.00 | 0.61 | 1.65 | 1.00 | |
| R-low, permissive | 42/127 | 1.21 | 0.82 | 1.79 | .34 | 53/126 | 0.85 | 0.61 | 1.20 | .36 | |
| Expression and TCE4.1 | Matched | 67/250 | 1.00 | — | 96/237 | 1.00 | — | ||||
| R-high, nonpermissive | 43/98 | 1.88 | 1.28 | 2.77 | <.001 | 29/95 | 0.71 | 0.47 | 1.09 | .12 | |
| R-high, permissive | 28/70 | 1.76 | 1.13 | 2.75 | .01 | 15/65 | 0.54 | 0.31 | 0.93 | .03 | |
| R-low, nonpermissive | 27/89 | 1.11 | 0.71 | 1.74 | .65 | 35/91 | 0.71 | 0.48 | 1.05 | .08 | |
| R-low, permissive | 26/74 | 1.28 | 0.81 | 2.02 | .29 | 37/70 | 1.16 | 0.79 | 1.70 | .45 | |
.05 > P ≥ .01 are shown in bold and italic; P < .01 are shown in bold, italic, and underlined. Significant covariables retained for relapse/progression (Rel/prog): European Society for Blood and Marrow Transplantation risk score, graft manipulation, and transplant center. Significant covariables retained for aGVHD: HLA-DRB3/4/5 matching, graft manipulation, and transplant center. CI, confidence interval; D, donor; Events, number of events in the risk category for the specified outcome; n, number of patients in the risk category for the specified outcome; R, recipient.
The number of patients/events for the regressions with expression is N = 579/191 and 558/212 for aGVHD ≥2 and Rel/prog, respectively.
Patients with nonmalignant disorder are excluded from analyses on relapse.
Not interpretable (NI) because of the very small number of patients in this group.